📣 VC round data is live. Check it out!

Ruentex Industries Valuation Multiples

Discover Ruentex Industries' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Welspun Living, Isiklar Enerji ve Yapi, China Hi-Tech Group, Trident and more.

Ruentex Industries Overview

About Ruentex Industries

Ruentex Industries Ltd is engaged in the textile business, including manufacturing, processing, dyeing and finishing, printing, and marketing of woven fabrics, garments, knitted fabrics, and woven fabric items, and the construction business, including commissioning of construction companies to build public housing projects and office buildings as well as leasing and sales of property. Its reportable segments include Textile segment, Retail segment, and Hypermarket segment.


Founded

1976

HQ

Taiwan

Employees

472

Sectors

Financials (FY)

Revenue: $77M
EBITDA: $325M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Ruentex Industries Financials

Ruentex Industries reported last fiscal year revenue of $77M and EBITDA of $325M.

In the same fiscal year, Ruentex Industries generated $33M in gross profit, $325M in EBITDA, and $309M in net income.


Ruentex Industries P&L

In the most recent fiscal year, Ruentex Industries reported revenue of $77M and EBITDA of $325M.

Ruentex Industries is profitable as of last fiscal year, with gross margin of 43%, EBITDA margin of 421%, and net margin of 401%.

See analyst estimates for Ruentex Industries
Last FY202320242025202620272028
Revenue$77M$85M$92M$77M
Gross Profit$33M$30M$35M$33M
Gross Margin43%35%38%43%
EBITDA$325M$256M$455M$325M
EBITDA Margin421%301%494%421%
EBIT Margin7%2%7%7%
Net Profit$309M$239M$432M$309M
Net Margin401%280%469%401%
Net Debt$179M---

Financial data powered by Morningstar, Inc.

Ruentex Industries Stock Performance

Ruentex Industries has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Ruentex Industries' stock price is $1.44.

Ruentex Industries share price increased by 2.8% in the last 30 days, and decreased by 14.1% in the last year.

Ruentex Industries has an EPS (earnings per share) of $0.29.

See more trading valuation data for Ruentex Industries
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B2.8%2.8%-2.9%-14.1%$0.29

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Ruentex Industries Valuation Multiples

Ruentex Industries trades at 22.3x EV/Revenue multiple, and 5.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Ruentex Industries

Ruentex Industries Financial Valuation Multiples

As of June 2, 2026, Ruentex Industries has market cap of $2B and EV of $2B.

Ruentex Industries has a P/E ratio of 5.0x.

Last FY202320242025202620272028
EV/Revenue22.3x20.1x18.7x22.3x
EV/EBITDA5.3x6.7x3.8x5.3x
EV/EBITn/mn/mn/mn/m
EV/Gross Profit52.3x57.6x49.0x52.3x
P/E5.0x6.4x3.6x5.0x
EV/FCFn/m(195.6x)(118.2x)n/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Ruentex Industries Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Ruentex Industries Margins & Growth Rates

In the most recent fiscal year, Ruentex Industries reported gross margin of 43%, EBITDA margin of 421%, and net margin of 401%.

See estimated margins and future growth rates for Ruentex Industries

Ruentex Industries Margins

Last FY20242025202720282029
Gross Margin43%38%43%
EBITDA Margin421%494%421%
EBIT Margin7%7%7%
Net Margin401%469%401%
FCF Margin5%(16%)5%

Ruentex Industries Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth8%(16%)
Gross Profit Growth18%(6%)
EBITDA Growth77%(29%)
EBIT Growth226%(25%)
Net Profit Growth81%(29%)
FCF Growth66%(125%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Ruentex Industries Operational KPIs

Ruentex Industries' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Ruentex Industries
Last FY202320242025202620272028
Revenue per Employee$0.2M---
Opex per Employee$0.1M---
S&M Expenses to Revenue25%23%21%25%
G&A Expenses to Revenue11%10%10%11%
Opex to Revenue36%33%31%36%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Ruentex Industries Competitors

Ruentex Industries competitors include Welspun Living, Isiklar Enerji ve Yapi, China Hi-Tech Group, Trident, Albany International, Vardhman Textiles, Swan Corp, Lenzing, Coats Group and James Halstead.

Most Ruentex Industries public comparables operate across Textiles.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Welspun Living1.6x1.6x17.7x17.1x
Isiklar Enerji ve Yapi19.0x-(445.4x)-
China Hi-Tech Group100.8x-(57.0x)-
Trident2.0x2.0x14.0x15.2x
Albany International1.8x1.8x29.1x15.8x
Vardhman Textiles1.8x1.8x11.9x13.3x
Swan Corp2.4x-18.8x-
Lenzing0.9x0.9x6.3x6.4x

This data is available for Pro users. Sign up to see all Ruentex Industries competitors and their valuation data.

Start Free Trial

Investments by Ruentex Industries

Ruentex Industries has invested in 2 companies to date.

Latest investment by Ruentex Industries was on November 11th 2021. Ruentex Industries invested in Ignis Therapeutics in their $180M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Ruentex Industries

Ignis Therapeutics
RenBio
Description
Ignis Therapeutics is a biotechnology company developing central nervous system therapies targeting unmet needs in neurology and psychiatry. Its pipeline includes small-molecule drugs advancing through preclinical stages for conditions like depression and schizophrenia. Headquartered in Europe, Ignis Therapeutics partners with CROs for clinical trials and regulatory submissions.
RenBio is a Boston-based biotechnology firm engineering antibody therapies via its MYO platform, which uses muscle cells as factories from DNA-encoded designs. The approach targets cancer, inflammatory disorders, rare diseases, viral infections, and autoimmunity.
HQ CountryChinaUnited States
HQ City
Shanghai
New York City, NY
Deal Date11 Nov 202120 May 2021
RoundSeries ASeries A
Raised$180M$24M
Investors6 Dimensions Capital; Goldman Sachs; HBM Healthcare Investments; KB Investment; Mubadala Energy; Ruentex Industries; WTT InvestmentRuentex Industries
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Ruentex Industries investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Ruentex Industries

When was Ruentex Industries founded?Ruentex Industries was founded in 1976.
Where is Ruentex Industries headquartered?Ruentex Industries is headquartered in Taiwan.
How many employees does Ruentex Industries have?As of today, Ruentex Industries has over 472 employees.
Is Ruentex Industries publicly listed?Yes, Ruentex Industries is a public company listed on Taiwan Stock Exchange.
What is the stock symbol of Ruentex Industries?Ruentex Industries trades under 2915 ticker.
When did Ruentex Industries go public?Ruentex Industries went public in 1977.
Who are competitors of Ruentex Industries?Ruentex Industries main competitors include Welspun Living, Isiklar Enerji ve Yapi, China Hi-Tech Group, Trident, Albany International, Vardhman Textiles, Swan Corp, Lenzing, Coats Group, James Halstead.
What is the current market cap of Ruentex Industries?Ruentex Industries' current market cap is $2B.
What is the current revenue of Ruentex Industries?Ruentex Industries' last fiscal year revenue is $77M.
What is the current EV/Revenue multiple of Ruentex Industries?Current revenue multiple of Ruentex Industries is 22.3x.
Is Ruentex Industries profitable?No, Ruentex Industries is not profitable.
How many companies Ruentex Industries has acquired to date?Ruentex Industries hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Ruentex Industries has invested to date?As of June 2026, Ruentex Industries has invested in 2 companies.
What was the last Ruentex Industries investment?On 11th November 2021 Ruentex Industries invested in Ignis Therapeutics, participating in a $180M Series A round, alongside 6 Dimensions Capital, Goldman Sachs, HBM Healthcare Investments, KB Investment, Mubadala Energy, and WTT Investment.
In what companies Ruentex Industries invested in?Ruentex Industries invested in Ignis Therapeutics and RenBio.

See public comps similar to Ruentex Industries

Lists including Ruentex Industries

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial